Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review

INTRODUCTION: Stage III melanoma, also referred to as regional metastatic melanoma, has five-year survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this high-risk population, patients undergo resection of primary tumors and all involved nodal basins. Syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuyama, Sonia, Gonzalez, Rene, Lewis, Karl D
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963921/
https://www.ncbi.nlm.nih.gov/pubmed/21042541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963921/
https://www.ncbi.nlm.nih.gov/pubmed/21042541

Ejemplares similares